Clinical Trials Logo

Cancer of Unknown Primary Site clinical trials

View clinical trials related to Cancer of Unknown Primary Site.

Filter by:

NCT ID: NCT03498521 Active, not recruiting - Clinical trials for Cancer of Unknown Primary Site

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

CUPISCO
Start date: July 10, 2018
Phase: Phase 2
Study type: Interventional

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.

NCT ID: NCT03278600 Completed - Clinical trials for Cancer of Unknown Primary Site

Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary

Start date: September 18, 2017
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the value of tissue-of-origin (ORIGIN-PanCA○R) profiling in predicting primary site and directing therapy in patients with cancer of unknown primary.

NCT ID: NCT03053466 Completed - Solid Tumor Clinical Trials

APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors

Start date: March 27, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and recommended dose schedule of APL-501 in individuals with advanced or relapsed or recurrent solid tumors.

NCT ID: NCT01845337 Completed - Pancreatic Cancer Clinical Trials

Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine

TOFFEE
Start date: February 5, 2014
Phase: Phase 2
Study type: Interventional

Capecitabine is a chemotherapy drug used to treat many types of cancer including bowel and stomach cancer. Unfortunately a side effect of this drug is that it causes heart problems including heart attacks. An alternative drug, called teysuno is used extensively in other countries instead of capecitabine and appears to have less of a bad effect on the heart whilst still killing cancer cells. This study will investigate the effect of these two drugs on the heart and blood vessels and will be the first of its kind in humans.